Infinity Pharmaceuticals, Inc.

OTCPK:INFI.Q Stock Report

Market Cap: US$90.0

Infinity Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Infinity Pharmaceuticals's earnings have been declining at an average annual rate of -14.5%, while the Biotechs industry saw earnings growing at 15.8% annually. Revenues have been declining at an average rate of 54% per year.

Key information

-14.5%

Earnings growth rate

-2.9%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-54.0%
Return on equityn/a
Net Margin-1,593.9%
Last Earnings Update30 Jun 2023

Recent past performance updates

Recent updates

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

Nov 10
Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

Infinity Pharmaceuticals: Waiting For A Deal

Sep 08

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

May 23
Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

We're Hopeful That Infinity Pharmaceuticals (NASDAQ:INFI) Will Use Its Cash Wisely

Dec 29
We're Hopeful That Infinity Pharmaceuticals (NASDAQ:INFI) Will Use Its Cash Wisely

Investigating Infinity Pharmaceuticals

Nov 25

Infinity Pharmaceuticals (NASDAQ:INFI) Is In A Good Position To Deliver On Growth Plans

Jul 18
Infinity Pharmaceuticals (NASDAQ:INFI) Is In A Good Position To Deliver On Growth Plans

Increases to Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) CEO Compensation Might Cool off for now

Jun 03
Increases to Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) CEO Compensation Might Cool off for now

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Deliver On Growth Plans?

Apr 13
Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Deliver On Growth Plans?

Are Institutions Heavily Invested In Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) Shares?

Feb 19
Are Institutions Heavily Invested In Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) Shares?

Can You Imagine How Jubilant Infinity Pharmaceuticals' (NASDAQ:INFI) Shareholders Feel About Its 147% Share Price Gain?

Jan 15
Can You Imagine How Jubilant Infinity Pharmaceuticals' (NASDAQ:INFI) Shareholders Feel About Its 147% Share Price Gain?

Infinity Pharma to start new registration-enabling eganelisib study in urothelial cancer

Jan 06

Will Infinity Pharmaceuticals (NASDAQ:INFI) Spend Its Cash Wisely?

Dec 11
Will Infinity Pharmaceuticals (NASDAQ:INFI) Spend Its Cash Wisely?

Infinity Pharma slides after eganelisib data presentation at Breast Cancer Symposium

Dec 09

Infinity Pharmaceutical Reaching Vital New Staging Posts

Dec 01

Revenue & Expenses Breakdown

How Infinity Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:INFI.Q Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 233-41140
31 Mar 233-43160
31 Dec 223-44130
30 Sep 223-47140
30 Jun 222-47140
31 Mar 222-46140
31 Dec 212-45140
30 Sep 212-44140
30 Jun 212-43130
31 Mar 212-41130
31 Dec 202-40120
30 Sep 202-41130
30 Jun 201-43130
31 Mar 201-44140
31 Dec 193-47140
30 Sep 193-44150
30 Jun 1925-19140
31 Mar 1924-16140
31 Dec 1822-11140
30 Sep 1822-10150
30 Jun 186-31160
31 Mar 186-41190
31 Dec 176-42220
30 Sep 176-57240
30 Jun 170-70250
31 Mar 1790300
31 Dec 1619-30350
30 Sep 1628-46370
30 Jun 1611915410
31 Mar 16114-76390
31 Dec 15109-128370
30 Sep 15104-129350
30 Jun 15174-71330
31 Mar 15169-68310
31 Dec 14165-17290
30 Sep 14161-1028100
30 Jun 140-14528100
31 Mar 140-14227100
31 Dec 130-127280
30 Sep 130-1412774
30 Jun 130-882674
31 Mar 1322-712774

Quality Earnings: INFI.Q is currently unprofitable.

Growing Profit Margin: INFI.Q is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: INFI.Q is unprofitable, and losses have increased over the past 5 years at a rate of 14.5% per year.

Accelerating Growth: Unable to compare INFI.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: INFI.Q is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).


Return on Equity

High ROE: INFI.Q's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies